ProCE Banner Activity

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer

Slideset Download
Conference Coverage
Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.

Released: June 04, 2015

Expiration: June 02, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation